TCTR20201022004招募中不适用
Effectiveness and Safety of Recombinant Human Erythropoietin on Patient Survival Rate during Severe Sepsis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- one
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •1.Participants who admitted to intensive care unit due to sepsis/ septic shock.
- •2.Participants who age of 18 years or older with received erythropoietin according to their underlying disease.
排除标准
- •1. Participants with missing clinical and laboratory data.
- •2. Participants who have been referred to another hospital.
- •3. Participants who have been treated with alternate to standard sepsis bundle scheme for sepsis and/or septic shock treatment as described in sepsis management guidelines.
研究者
相似试验
已完成
2 期
The Effect of Erythropoeitin on Anemia of PrematurityAnemia of Prematurity.Anaemia of prematurityIRCT201112265110N2Vice Chancellor for Research and Tchnology, Hamadan University of Medical Sciences30
暂停
1 期
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I.Acute Cerebral Ischemic Stroke.RPCEC00000078Center of Molecular Inmunology(CIM)20
尚未招募
1 期
iorEPOCIM-Stroke-Phase IStrokeRPCEC00000136Center of Molecular Inmunology (CIM)20
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60
已完成
4 期
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338